Rubius Therapeutics Exits Rare Disease Space, Discontinues PKU Trial

Rubius Therapeutics is deprioritizing its RTX-134 program for the treatment of phenylketonuria (PKU), as well as its other rare disease programs, according to a company press release.

The press release sited multiple factors contributing to the decision, including delays in the RTX-134 program and “uninterpretable” results from the first patient dosed in the Phase 1b PKY trial for the experimental treatment. The Phase 1b clinical trial for PKU will be discontinued.

Read the full press release here.